Hyperprogressive disease in patients with non‐small cell lung cancer treated with nivolumab: A case series

Nivolumab is an anti‐PD‐1 blocking monoclonal antibody approved for the treatment of non‐small cell lung cancer (NSCLC). However, some patients on immunotherapy may experience rapid progression and worsening clinical status, known as hyperprogressive disease. We retrospectively reviewed the clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanazu, Masaki, Edahiro, Ryuya, Krebe, Hiroyuki, Nishida, Kohei, Ishijima, Mikako, Uenami, Takeshi, Akazawa, Yuki, Yano, Yukihiro, Yamaguchi, Toshihiko, Mori, Masahide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2018
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6275832/
https://www.ncbi.nlm.nih.gov/pubmed/30328672
http://dx.doi.org/10.1111/1759-7714.12894

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6275832/
https://www.ncbi.nlm.nih.gov/pubmed/30328672
http://dx.doi.org/10.1111/1759-7714.12894

Ejemplares similares